Illustration of a gene bound by a molecule of estrogen in the nucleus of an estrogen-sensitive breast cancer cell. It is activated, thus initiating the cell cycle. This genetic switch is a potential target for anticancer therapy. The gene's product RNA is a target for RNA interference (RNAi) technology.